Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 7,024 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Volunteers. Clear all

Conditions: Healthy Subjects
Interventions: 0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab, Saline solution for intravenous infusion; Biological · Other
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Self-declared Healthy Subjects
Interventions: Not listed
Lead sponsor: IPGDx, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Nokomis, Florida • Harrisville, Michigan

Conditions: Opioid-Related Disorders, Substance-Related Disorders
Interventions: 0% N2O, 40% N2O; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 32 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1993 – 1995
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Participants, Tobacco Smokers
Interventions: Der f; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Volunteer
Interventions: ABBV-101; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy
Interventions: efavirenz, fenofibric acid 105 mg; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Alzheimer Disease
Interventions: [18F]NAV4694; Drug
Lead sponsor: Navidea Biopharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: New Haven, Connecticut • Chicago, Illinois • Elk Grove Village, Illinois + 4 more

Conditions: Myocardial Infarct
Interventions: RNS60, Placebo; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Healthy Volunteer
Interventions: Icovamenib, Icovamenib HPMC; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: LY3074828; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Skin Irritancy Potential
Interventions: Chlorhexidine Gluconate, Hibi Universal Bathing System, 0.1% SLS, Distilled Water; Drug · Device · Other
Lead sponsor: Molnlycke Health Care AB; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Healthy Volunteer
Interventions: Information absent, Information; Other
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: ivosidenib (AG-120); Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Participants
Interventions: [14C]-darigabat; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Subjects
Interventions: Placebo, E2609, Moxifloxacin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: Danicamtiv, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy, Psychedelic Experiences, Sleep
Interventions: Psilocybin, Clonidine, Saline; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Local Anaesthetic Complication, Pain
Interventions: Kinetic Anesthesia Device, Control; Device · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Enasidenib; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer's Disease, Healthy Volunteer
Interventions: [11C]RO6924963, [11C]RO6931643, [18F]RO6958948; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Tourette Syndrome, Tic Disorders
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Participants
Interventions: Eptinezumab Mammalian Cell Line, Eptinezumab Yeast Cell Line; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Daytona Beach, Florida • Madison, Wisconsin

Search by objective public record fields.

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

Comparison of Bioimpedance Body Composition Device Measurements

Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2

Evaluation of the Effect of a Nasal Allergen Challenge With Dermatophagoides Farinae Extract on Nasal Airway Inflammation in Allergic Individuals, Comparing E-cigarette Users to Cigarette Smokers and Non-smokers.

A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

Food Effect Study in Healthy Volunteers

A Study of LY3074828 in Healthy Participants

A 96-hour Patch Test Study Using Healthy Human Volunteers to Assess the Skin Irritation Potential of 11 Topically Applied Formulations

Patient Provider Communication and Interaction in a Virtual Clinical Setting

Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

Consciousness, Psilocybin, and Well-Being

Kinetic Anesthesia Device Study

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions

Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults

Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants

Brain Dynamics Involved in Generating Tics and Controlling Voluntary Movement

A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines